查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2001034

癌症免疫療法藥物研發外包市場：按服務類型、治療方法、工作流程階段和最終用戶分類－2026年至2032年全球市場預測

Cancer Immunotherapy Drug Discovery Outsourcing Market by Service Type, Therapeutic Modality, Workflow Stage, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年癌症免疫療法藥物開發外包市值為 9,622.7 億美元，預計到 2026 年將成長至 1.08621 兆美元，年複合成長率為 14.15%，到 2032 年將達到 2.43162 兆美元。

主要市場統計數據
基準年 2025 9622.7億美元
預計年份：2026年 1.08621兆美元
預測年份：2032年 24316.2億美元
複合年成長率 (%) 14.15%

全面概述了外包為何已成為癌症免疫療法藥物發現和轉化開發的戰略必要性。

本文引言部分為希望了解癌症免疫療法藥物研發外包實踐演變的讀者提供了一個策略框架，使其能夠獲得簡潔而全面的概述。細胞工程、核酸平台和免疫調節生技藥品領域的最新進展，重新定義了贊助公司將技術任務外包給外部合作夥伴的方式和地點。這些變化反映了整個產業在縮短研發週期的同時，維持日益複雜的轉換計畫所需的科學嚴謹性的更廣泛需求。

一個策略性的技術轉折點：重新定義癌症免疫療法藥物發現和開發中的合作夥伴選擇和能力要求。

該領域的變革性變化源自於科學突破與商業性壓力的交匯，強調敏捷性和技術深度。隨著CAR-T細胞療法、RNA疫苗和新一代查核點調控等治療方法的日益成熟，對外部合作夥伴的技術需求也不斷提高。申辦方日益尋求涵蓋從先導化合物發現到臨床前評估（支持IND申報）乃至臨床階段支持的一體化服務，這反映出他們傾向於選擇數量較少但能力更強的合作夥伴，以管理複雜的、特定治療方法的工作流程。

分析 2025 年貿易政策措施如何從結構上影響免疫療法計畫的採購韌性、供應商多元化和製造本地化。

美國於2025年實施的關稅措施的累積影響，為參與免疫療法開發外包的相關人員帶來了成本壓力和物流方面的限制。這些措施影響了專用試劑、一次性組件和某些生技藥品相關設備的進口，進而影響了供應商選擇和庫存管理。嚴重依賴跨境供應鏈的機構面臨著更長的前置作業時間，並且必須重新評估關鍵原料的儲備，尤其是在需要客製化細胞處理耗材和病毒載體組件的治療方法。

將服務能力、治療方式、工作流程階段和最終用戶優先順序與可操作的外包策略聯繫起來的詳細細分見解。

關鍵的細分洞察揭示了不同服務類型、治療模式、工作流程階段和最終用戶之間的策略重點和技術依賴性差異，從而能夠基於這些洞察做出最佳採購決策。從服務類型角度來看，臨床開發服務需要具備涵蓋 I 期、II 期和 III 期的詳細通訊協定設計和執行能力。同時，數據管理和生物統計學越來越側重於生物資訊學、臨床數據管理和統計分析，以提取轉化訊號。生產支援強調 CMC 最佳化和製程開發，以實現可擴展的生產，而臨床前服務則優先考慮先導化合物的發現，包括穩健的標靶識別策略、先導化合物最佳化和臨床前安全性評估。監管支持在 IND 申請協助和監管策略諮詢方面仍然至關重要，尤其是在新的治療模式改變了監管機構對可比性和療效測試的要求的情況下。

影響美洲、歐洲、中東、非洲和亞太地區地域最佳化外包策略的區域趨勢和能力。

區域趨勢影響著申辦方的外包策略，主要歸因於各大區域在監管協調、人才儲備和基礎建設成熟度等方面的差異。在美洲，臨床試驗中心的集中、成熟的合約研發生產機構（CDMO）的存在，以及創投公司和大型企業建構的強大投資生態系統，促進了先進治療方法的快速應用。垂直整合的夥伴關係關係，整合了製程開發、GMP生產和後期臨床支持，為這些療法提供了強大支撐。這種環境有利於那些尋求快速進入臨床階段並需要整合分析能力以支持適應性測試設計的申辦者。

癌症免疫療法外包生態系統中成功服務供應商的競爭差異化因素和夥伴關係模式

對主要企業的分析凸顯了競爭格局的現狀：技術專長、平台整合以及能夠降低專案風險的夥伴關係模式是企業實現差異化的關鍵所在。領先的供應商正投資於特定療法的檢測組合和內部生產技術，以支持CAR-T細胞療法和溶瘤病毒等複雜療法。此外，他們也透過整合先進的資料管理和生物資訊服務來強化自身的價值提案，將高維度生物學測量結果轉化為符合監管要求的證據。

為採購和研發領導者提供切實可行的優先建議，以增強韌性並加速免疫療法計畫。

針對行業領導者的可操作建議強調了增強專案韌性和加速轉化研究進展的實際步驟。首先，優先考慮能夠提供深厚的、特定療法專業知識的夥伴關係。例如，在細胞療法和病毒載體專案中，選擇在CMC最佳化和GMP製程開發方面擁有良好業績記錄的供應商，以降低規模化生產的風險。其次，在專案規劃的早期階段整合資料管理和進階生物統計學，以便在樣本採集、檢測方法選擇和生物資訊流程中產生符合監管要求的終點指標，從而實現適應性決策。

我們透明嚴謹的調查方法，結合對關鍵相關人員的訪談、二手資料的整合和結構化檢驗，為可操作的結論提供了支持。

本分析的調查方法結合了結構化的初步研究、專家檢驗和針對性的次要研究，以確保研究的嚴謹性和相關性。初步資料收集包括對研發部門高階領導、臨床營運經理、監管負責人和服務供應商高階主管的訪談，以了解實際決策標準和營運限制。這些訪談為揭示能力差距、典型的供應商合作模式以及不斷變化的資料管理和生物統計支持期望奠定了基礎。

一份簡潔、全面的分析報告，重點闡述了免疫療法藥物發現和開發外包的策略意義、營運重點和基本考慮因素。

總之，癌症免疫療法藥物發現和開發的外包模式正變得更加戰略化、專業化和數據主導。申辦者現在期望外部合作夥伴能夠提供從藥物發現階段到臨床階段的整合能力，尤其著重於CMC製程開發、特異性療法檢測方法開發和進階分析。政策變化和供應鏈趨勢凸顯了地理多元化的重要性，以及製定穩健的籌資策略以確保專案進度和產品品質的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：癌症免疫療法藥物研發外包市場：依服務類型分類

  • 臨床開發服務
    • 第一階段
    • 第二階段
    • 第三階段
  • 資料管理與生物統計學
    • 生物資訊學
    • 臨床數據管理
    • 統計分析
  • 製造支持
    • CMC最佳化
    • 製程開發
  • 臨床前服務
    • 點擊量和潛在客戶開發
    • 先導藥物最適化
    • 臨床前安全性評估
    • 目標識別
  • 藥物支持
    • IND申請支持
    • 監理策略諮詢

第9章：癌症免疫療法藥物研發外包市場：依治療方法分類

  • 癌症疫苗
    • 樹突細胞疫苗
    • DNA疫苗
    • 胜肽疫苗
    • RNA疫苗
  • CAR-T細胞療法
    • BCMA靶點
    • CD19標靶
  • 查核點抑制劑
    • CTLA-4抑制劑
    • PD-1抑制劑
    • PD-L1抑制劑
  • 細胞激素療法
    • 集落刺激因子
    • 干擾素
    • 白細胞介素
  • 單株抗體
    • 嵌合體
    • 完全人形
    • 人性化
    • 小鼠來源
  • 溶瘤病毒療法
    • 基於腺病毒的
    • HSV 基礎
    • 基於呼腸孤病毒

第10章：癌症免疫療法藥物研發外包市場：依工作流程階段分類

  • 臨床階段
    • 第一階段
    • 第二階段
    • 第三階段
  • 發展階段
    • IND申請準備檢查
    • 臨床前開發
  • 藥物發現階段
    • 命中發現
    • 命中檢驗
    • 先導化合物搜尋
    • 目標識別
  • 核准後階段
    • 藥物安全監測
    • 第四階段試驗

第11章：癌症免疫療法藥物開發外包市場：以最終用戶分類

  • 學術研究機構
  • 生技公司
  • 政府附屬研究機構
  • 製藥公司

第12章：癌症免疫療法藥物研發外包市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：癌症免疫療法藥物研發外包市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：癌症免疫療法藥物研發外包市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國癌症免疫療法藥物開發外包市場。

第16章：中國癌症免疫療法藥物研發外包市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • BPS Bioscience, Inc.
  • Celentyx Ltd.
  • Charles River Laboratories International, Inc.
  • Covance, Inc.
  • Crown Bioscience, Inc.
  • Curia Inc.
  • Dalton Pharma Services
  • DiscoverX Corporation
  • Eurofins Scientific
  • Evotec SE
  • Explicyte
  • Genscript BIoTech Corporation
  • HD Biosciences Co., Ltd.
  • Horizon Discovery Group PLC
  • ImmunXperts SA
  • Jubilant Life Sciences Limited
  • Labcorp
  • Oncodesign Precision Medicine Opm SA
  • Personalis, Inc.
  • Promega Corporation
  • STC Biologics Inc.
  • TCG Lifesciences Pvt. Limited
  • WuXi AppTec Co., Ltd.
Product Code: MRR-205091A88709

The Cancer Immunotherapy Drug Discovery Outsourcing Market was valued at USD 962.27 billion in 2025 and is projected to grow to USD 1,086.21 billion in 2026, with a CAGR of 14.15%, reaching USD 2,431.62 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 962.27 billion
Estimated Year [2026] USD 1,086.21 billion
Forecast Year [2032] USD 2,431.62 billion
CAGR (%) 14.15%

Comprehensive contextual overview explaining why outsourcing has become a strategic imperative for cancer immunotherapy drug discovery and translational development

The introduction sets the strategic frame for readers who need a concise but comprehensive orientation to the evolving practice of outsourcing in cancer immunotherapy drug discovery. Over recent years, advances in cellular engineering, nucleic acid platforms, and immune-modulating biologics have redefined where and how sponsor organizations allocate technical work to external partners. These shifts reflect a broader industry imperative: to compress timelines while preserving the scientific rigor required for increasingly complex translational programs.

This report opens by articulating the primary drivers that compel companies to outsource, including the need for specialized preclinical assay suites, scalable manufacturing processes for cell and gene therapies, and the bioinformatics infrastructure necessary to manage high-dimensional translational data. It also highlights the counterbalances sponsors face, such as regulatory complexity, supply chain fragility, and rising expectations for quality and reproducibility. The introduction therefore positions outsourcing not merely as a cost-management tool but as a strategic instrument for capability augmentation, risk sharing, and accelerated learning across discovery, development, and early clinical proof-of-concept.

Strategic and technological inflection points reshaping partner selection and capability requirements across cancer immunotherapy discovery and development

Transformative shifts in the landscape are driven by converging scientific breakthroughs and commercial pressures that reward agility and technical depth. The maturation of modalities such as CAR T cell therapies, RNA-based vaccines, and next-generation checkpoint modulation has expanded the technical scope required of external partners. Sponsors increasingly demand integrated offerings that span hit and lead discovery through IND-enabling preclinical assessments and clinical stage support, reflecting a preference for fewer, more capable collaborators who can manage complex modality-specific workflows.

In parallel, technological enablers such as single-cell sequencing, multiplexed immunophenotyping, and machine learning-driven bioinformatics have raised the bar for data management and biostatistics support. As a result, the market is experiencing a clearer segmentation between providers that offer advanced analytics and those that focus on traditional wet-lab services. These trends are prompting a redefinition of partnerships: successful vendors now demonstrate not only technical competence in preclinical safety assessment, CMC optimization, or process development, but also robust data integration, regulatory strategy, and commercialization support. Consequently, sponsors are reorganizing their sourcing strategies to prioritize partners who can co-design experiments, translate complex translational signals into regulatory-ready dossiers, and scale manufacturing processes from early development to clinical and post-approval stages.

Analysis of how 2025 trade policy actions have structurally influenced sourcing resilience, supplier diversification, and manufacturing localization in immunotherapy programs

The cumulative impact of United States tariffs implemented in 2025 introduced discrete cost pressures and logistical constraints for stakeholders engaged in outsourced immunotherapy development. These measures affected the importation of specialized reagents, single-use components, and certain biologics-related hardware, which in turn influenced supplier selection and inventory practices. Organizations that relied heavily on cross-border supply chains experienced increased lead times and needed to reassess buffer stocks for critical inputs, particularly for modalities requiring bespoke cell-processing consumables and viral vector components.

In response, many sponsors accelerated efforts to localize key manufacturing steps or to diversify the supplier base so that essential CMC optimization and process development activities could continue unimpeded. Regulatory interactions became more prominent in vendor evaluation as sponsors sought assurance that documentation could withstand jurisdictional scrutiny if production footprints shifted. Additionally, the tariff environment highlighted the value of service models that reduce dependency on imported hardware by offering turnkey solutions and onshore clinical development services. Overall, the policy changes reinforced a strategic pivot toward resilient, geographically diversified outsourcing strategies that integrate procurement foresight with technical and regulatory mitigation plans.

In-depth segmentation insights that connect service capabilities, therapeutic modalities, workflow stages, and end-user priorities to practical outsourcing strategies

Key segmentation insights reveal how strategic priorities and technical dependencies vary by service type, therapeutic modality, workflow stage, and end user, informing tailored sourcing decisions. In the domain of service type, clinical development services require deep protocol design and execution capabilities across Phase I, Phase II, and Phase III, while data management and biostatistics increasingly center on bioinformatics, clinical data management, and statistical analysis to extract translational signals. Manufacturing support emphasizes CMC optimization and process development to enable scalable production, and preclinical services prioritize hit and lead discovery, lead optimization, and preclinical safety assessment with robust target identification strategies. Regulatory affairs support remains essential for IND filing support and regulatory strategy consulting, especially when novel modalities change the regulatory expectations for comparability and potency assays.

Therapeutic modality exerts a strong influence on vendor selection and operational risk. Cancer vaccines span dendritic cell, DNA, peptide, and RNA platforms each with distinct formulation and immunogenicity testing requirements. CAR T cell therapy programs differentiate technical needs between BCMA-targeted and CD19-targeted constructs, influencing vector choice and potency assays. Checkpoint inhibitors present distinct pathways based on CTLA-4, PD-1, and PD-L1 mechanisms, requiring tailored pharmacodynamic and biomarker strategies. Cytokine therapies demand expertise across colony stimulating factors, interferons, and interleukins, while monoclonal antibodies vary across chimeric, fully human, humanized, and murine formats with corresponding CMC implications. Oncolytic virus therapy further segments by platform, including adenovirus, HSV, and reovirus based approaches, each with unique GMP requirements for vector manufacturing and release testing.

Workflow stage segmentation clarifies where external expertise delivers the highest marginal value. Discovery-stage activities such as hit discovery, hit validation, lead discovery, and target identification benefit from specialized assay platforms and rapid iteration. Development-stage work focused on IND-enabling studies and preclinical development requires cross-functional coordination between toxicology, analytical development, and process engineers. Clinical stage initiatives across Phase I-III rely on clinical operations depth, while post-approval stage responsibilities emphasize pharmacovigilance and Phase IV studies that sustain safety surveillance and label expansion. Finally, end users drive different partnership dynamics: academic research institutes often seek modular, hypothesis-driven services; biotechnology companies prioritize speed and flexibility; government research institutes emphasize reproducibility and public health impact; and pharmaceutical companies demand integrated programs that de-risk later-stage regulatory submission and commercialization.

Regional dynamics and capability contrasts that inform geographically optimized outsourcing strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics shape how sponsors approach outsourcing, as factors such as regulatory harmonization, talent pools, and infrastructure maturity differ across major geographies. In the Americas, a concentration of clinical trial sites, established CDMOs, and deep venture and corporate investment ecosystems have fostered rapid adoption of advanced modalities and supported vertically integrated partnerships that combine process development, GMP manufacturing, and late-stage clinical support. This environment favors sponsors seeking speed to clinic and integrated analytics capabilities that can support adaptive trial designs.

Europe, Middle East & Africa presents a mosaic of regulatory frameworks and centers of excellence that enables targeted collaborations for specialized assay development, biologics manufacturing, and translational immuno-oncology research. Variability in national regulatory timelines and reimbursement environments prompts sponsors to design geographically optimized development plans that leverage local scientific expertise while addressing cross-border regulatory convergence. In contrast, Asia-Pacific has emerged as a hub for scalable manufacturing capacity, a growing base of skilled cell and gene therapy scientists, and an expanded clinical trial infrastructure. Governments and private investors in the region have prioritized biotech industrialization, which has translated into increased availability of CMC optimization services, process development talent, and onshore vector manufacturing options. Sponsors operating across these regions adopt hybrid strategies that combine local execution for cost and capacity advantages with centralized coordination for regulatory alignment and data governance.

Competitive differentiation and partnership models that define successful service providers in the cancer immunotherapy outsourcing ecosystem

Key companies insights point to a competitive environment where differentiation stems from technical specialization, platform integration, and partnership models that reduce program risk. Leading providers invest in modality-specific assay portfolios and in-house manufacturing technologies to support complex modalities such as CAR T cell therapies and oncolytic viruses. They also strengthen their value proposition by embedding advanced data management and bioinformatics services that convert high-dimensional biological readouts into regulatory-grade evidence.

Strategic alliances are increasingly common, with commercial biotechs, academic spinouts, and service providers forming project-based consortia to accelerate IND-enabling activities. Top-performing vendors demonstrate transparent quality systems, validated analytics, and the ability to scale CMC processes from bench to clinical lots. In parallel, a subset of organizations has differentiated by offering regulatory strategy consulting alongside IND filing support, thereby minimizing handoffs and accelerating submission readiness. The market reward goes to those firms that can demonstrate reproducible assay transfer, robust comparability strategies, and an integrated approach to managing manufacturing variability, supply continuity, and regulatory expectations across jurisdictions.

Practical and prioritized recommendations that procurement, research, and development leaders can implement to enhance resilience and accelerate immunotherapy programs

Actionable recommendations for industry leaders emphasize pragmatic steps to strengthen program resilience and accelerate translational progress. First, prioritize partnerships that offer modality-aligned depth; for example, select vendors with proven CMC optimization and GMP process development experience for cell and viral vector programs to reduce scale-up risk. Second, integrate data management and advanced biostatistics early in program planning so that sample collection, assay selection, and bioinformatics pipelines produce regulatory-grade endpoints and enable adaptive decision-making.

Third, reassess supply chain strategies by incorporating regional supplier diversification and buffer inventories for critical single-use components and reagents; this will mitigate exposure to external tariff or logistics shocks. Fourth, embed regulatory strategy consulting with technical workstreams to ensure that assay development, comparability plans, and documentation meet jurisdictional expectations ahead of IND submission. Fifth, consider modular contracting models that allow for phased scope increases as development milestones are met, enabling sponsors to maintain flexibility while securing priority access to vendor capacity. Finally, invest in vendor audits and technical transfer protocols that emphasize reproducibility and documentation quality, thereby reducing downstream delays and facilitating faster approvals.

Transparent and rigorous research methodology combining primary stakeholder interviews, secondary literature synthesis, and structured validation to support actionable conclusions

The research methodology underpinning this analysis combined structured primary research, expert validation, and targeted secondary review to ensure rigor and relevance. Primary data collection included interviews with senior R&D leaders, clinical operations heads, regulatory strategists, and service provider executives to capture real-world decision criteria and operational constraints. These discussions provided the foundation for mapping capability gaps, typical vendor engagement models, and the evolving expectations for data management and biostatistics support.

Secondary review synthesized peer-reviewed literature, regulatory guidance documents, and public disclosures to contextualize technological advances and policy changes that affect outsourcing models. Cross-validation was performed through triangulation of qualitative insights and document analysis, and findings were stress-tested in scenario exercises that model supply chain disruptions, modality-specific scale-up challenges, and regulatory pathway variability. Quality control measures included methodological transparency, clear inclusion criteria for interviewees, and iterative review cycles with domain experts to refine conclusions and recommendations.

Concise synthesis highlighting the strategic takeaways, operational priorities, and essential considerations for outsourcing immunotherapy discovery and development

In conclusion, outsourcing in cancer immunotherapy discovery and development is becoming more strategic, specialized, and data-driven. Sponsors now expect external partners to provide integrated capabilities that span discovery to clinical stages, with strong emphasis on CMC process development, modality-specific assay development, and advanced analytics. Policy changes and supply chain dynamics have underscored the importance of geographical diversification and the need for resilient sourcing strategies that preserve program timelines and product quality.

Moving forward, organizations that align early with partners capable of co-designing experiments, enabling scalable manufacturing, and translating complex biological signals into regulatory-ready evidence will gain the most leverage. The path to successful outsourcing requires deliberate vendor selection, early integration of regulatory and data strategies, and investment in robust technical transfer and quality assurance practices. Adopting these approaches will reduce development risk, improve reproducibility, and position programs to capitalize on the accelerating innovation in immuno-oncology.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Service Type

  • 8.1. Clinical Development Services
    • 8.1.1. Phase I
    • 8.1.2. Phase II
    • 8.1.3. Phase III
  • 8.2. Data Management And Biostatistics
    • 8.2.1. Bioinformatics
    • 8.2.2. Clinical Data Management
    • 8.2.3. Statistical Analysis
  • 8.3. Manufacturing Support
    • 8.3.1. CMC Optimization
    • 8.3.2. Process Development
  • 8.4. Preclinical Services
    • 8.4.1. Hit And Lead Discovery
    • 8.4.2. Lead Optimization
    • 8.4.3. Preclinical Safety Assessment
    • 8.4.4. Target Identification
  • 8.5. Regulatory Affairs Support
    • 8.5.1. IND Filing Support
    • 8.5.2. Regulatory Strategy Consulting

9. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Therapeutic Modality

  • 9.1. Cancer Vaccines
    • 9.1.1. Dendritic Cell Vaccines
    • 9.1.2. DNA Vaccines
    • 9.1.3. Peptide Vaccines
    • 9.1.4. RNA Vaccines
  • 9.2. CAR T Cell Therapy
    • 9.2.1. BCMA Targeted
    • 9.2.2. CD19 Targeted
  • 9.3. Checkpoint Inhibitors
    • 9.3.1. CTLA-4 Inhibitors
    • 9.3.2. PD-1 Inhibitors
    • 9.3.3. PD-L1 Inhibitors
  • 9.4. Cytokine Therapy
    • 9.4.1. Colony Stimulating Factors
    • 9.4.2. Interferons
    • 9.4.3. Interleukins
  • 9.5. Monoclonal Antibodies
    • 9.5.1. Chimeric
    • 9.5.2. Fully Human
    • 9.5.3. Humanized
    • 9.5.4. Murine
  • 9.6. Oncolytic Virus Therapy
    • 9.6.1. Adenovirus Based
    • 9.6.2. HSV Based
    • 9.6.3. Reovirus Based

10. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Workflow Stage

  • 10.1. Clinical Stage
    • 10.1.1. Phase I
    • 10.1.2. Phase II
    • 10.1.3. Phase III
  • 10.2. Development Stage
    • 10.2.1. IND Enabling Studies
    • 10.2.2. Preclinical Development
  • 10.3. Discovery Stage
    • 10.3.1. Hit Discovery
    • 10.3.2. Hit Validation
    • 10.3.3. Lead Discovery
    • 10.3.4. Target Identification
  • 10.4. Post Approval Stage
    • 10.4.1. Pharmacovigilance
    • 10.4.2. Phase IV Studies

11. Cancer Immunotherapy Drug Discovery Outsourcing Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Biotechnology Companies
  • 11.3. Government Research Institutes
  • 11.4. Pharmaceutical Companies

12. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cancer Immunotherapy Drug Discovery Outsourcing Market

16. China Cancer Immunotherapy Drug Discovery Outsourcing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. BPS Bioscience, Inc.
  • 17.6. Celentyx Ltd.
  • 17.7. Charles River Laboratories International, Inc.
  • 17.8. Covance, Inc.
  • 17.9. Crown Bioscience, Inc.
  • 17.10. Curia Inc.
  • 17.11. Dalton Pharma Services
  • 17.12. DiscoverX Corporation
  • 17.13. Eurofins Scientific
  • 17.14. Evotec SE
  • 17.15. Explicyte
  • 17.16. Genscript Biotech Corporation
  • 17.17. HD Biosciences Co., Ltd.
  • 17.18. Horizon Discovery Group PLC
  • 17.19. ImmunXperts SA
  • 17.20. Jubilant Life Sciences Limited
  • 17.21. Labcorp
  • 17.22. Oncodesign Precision Medicine Opm SA
  • 17.23. Personalis, Inc.
  • 17.24. Promega Corporation
  • 17.25. STC Biologics Inc.
  • 17.26. TCG Lifesciences Pvt. Limited
  • 17.27. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DATA MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DATA MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DATA MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATISTICAL ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATISTICAL ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATISTICAL ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CMC OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CMC OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CMC OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT AND LEAD DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT AND LEAD DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT AND LEAD DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SAFETY ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SAFETY ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SAFETY ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IND FILING SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IND FILING SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IND FILING SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY STRATEGY CONSULTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY STRATEGY CONSULTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY STRATEGY CONSULTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BCMA TARGETED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BCMA TARGETED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BCMA TARGETED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CD19 TARGETED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CD19 TARGETED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CD19 TARGETED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COLONY STIMULATING FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COLONY STIMULATING FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INTERLEUKINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INTERLEUKINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INTERLEUKINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MURINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MURINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MURINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ADENOVIRUS BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ADENOVIRUS BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ADENOVIRUS BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HSV BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HSV BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HSV BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REOVIRUS BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REOVIRUS BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REOVIRUS BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IND ENABLING STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IND ENABLING STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IND ENABLING STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE IV STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE IV STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE IV STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 218. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 219. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 222. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA